Uchida Tomoyuki, Takagi Yuki, Mizuno Akihiro, Okamura Hayao, Saito Hiroki, Ide Shiro, Ohara Shin, Inoue Morihiro, Hagihara Masao
Department of Hematology, Eiju General Hospital.
Rinsho Ketsueki. 2020;61(8):857-864. doi: 10.11406/rinketsu.61.857.
Nosocomial coronavirus disease 2019 (COVID-19) had occurred at our hospital. We retrospectively analyzed the differences between patients with nosocomial COVID-19 and either hematological disease (n=40) or other diseases (n=57). The analysis was completed within 60 days for surviving patients. Among the patients with hematological disease and those with other diseases, there were 21 (52.5%) and 20 (35.1%) deaths, respectively. Although the patients with hematological disease received favipiravir more frequently than patients with other diseases (21 [52.5%] vs. 15 [35.3%], respectively; P<0.05), their median overall survival was poor (29 days; P=0.078). Furthermore, the median duration from oxygen therapy initiation to death or intubation was significantly shorter in the patients with hematological disease (5 days [range, 1-17 days] vs. 10 days [1-24 days], respectively; P<0.05). Furthermore, the patients with hematological disease and nosocomial COVID-19 exhibited more marked respiratory failure and poorer outcomes leading to death in a shorter time period than the patients with other diseases and nosocomial COVID-19.
我院发生了医院获得性冠状病毒病2019（COVID-19）。我们回顾性分析了医院获得性COVID-19患者与血液系统疾病患者（n = 40）或其他疾病患者（n = 57）之间的差异。对存活患者在60天内完成了分析。在血液系统疾病患者和其他疾病患者中，分别有21例（52.5%）和20例（35.1%）死亡。尽管血液系统疾病患者比其他疾病患者更频繁地接受法匹拉韦治疗（分别为21例[52.5%]对15例[35.3%]；P<0.05），但其总生存中位数较差（29天；P = 0.078）。此外，血液系统疾病患者从开始氧疗到死亡或插管的中位持续时间明显更短（分别为5天[范围1 - 17天]对10天[1 - 24天]；P<0.05）。此外，与其他疾病合并医院获得性COVID-19的患者相比，血液系统疾病合并医院获得性COVID-19的患者表现出更明显的呼吸衰竭，且在更短时间内导致死亡的结局更差。
